Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | S100A9 | P06702 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15067048 | 0.94 | ALDH1A1 (0.48) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL22843394 | 0.84 | ALDH1A1 (0.48) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL3709323 | 0.82 | ALDH1A1 (0.68) | ALDH1A1LMNAMAPTNPSR1L3MBTL1 | |
| SCHEMBL31454281 | 0.82 | ALDH1A1 (0.72) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL1459863 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPTNPSR1 | |
| SCHEMBL1368654 | 0.81 | MAPT (0.42) | ALDH1A1LMNAMAPTHTTNPSR1 | |
| SCHEMBL2172819 | 0.80 | ALDH1A1 (0.56) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL516599 | 0.78 | ALDH1A1 (0.57) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL517787 | 0.78 | ALDH1A1 (0.57) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL2174000 | 0.77 | ALDH1A1 (0.57) | ALDH1A1LMNAGAAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448105-A1 | HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE | VIR Biotechnology, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240010641-A1 | N-Linked Glycosylation Inhibitors and Methods of Using Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-11 | — | — | US | disclosed |
| WO-2023114428-A1 | HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE | Vir Biotechnology, Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114428-A1 | HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE | Vir Biotechnology, Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2022051286-A1 | N-LINKED GLYCOSYLATION INHIBITORS AND METHODS OF USING SAME | YALE UNIVERSITY (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| WO-2019141131-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2019-07-25 | — | — | WO | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010641-A1 | N-Linked Glycosylation Inhibitors and Methods of Using Same | ENGASE, UGGT1, GALNT1 | ALDH1A1 2776/4885LMNA 1705/4885GAA 6/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | ALDH1A1 1794/4885LMNA 1293/4885GAA 1927/4885 |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | HRH2, HRH1, HRH3 | ALDH1A1 54/4885LMNA 4243/4885GAA 722/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | ALDH1A1 1794/4885LMNA 1293/4885GAA 1927/4885 |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | ALDH1A1 1794/4885LMNA 1293/4885GAA 1927/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | ALDH1A1 1794/4885LMNA 1293/4885GAA 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.